OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HPAD56

Hp Adhesives Ltd

Specialty ChemicalsVerified

Hp Adhesives Ltd maintains a strong liquidity position, with a current ratio of 4.61, indicating the company can easily cover its short-term obligations. The company's liquidity FPT (Fundamental Price Target) is supported by a robust operating cash flow of INR 227.84 million and a cash and equivalents balance of INR 90.99 million. The debt-to-equity ratio of 0.02 suggests a conservative capital structure with minimal leverage. In terms of profitability, the company's return on equity (ROE) of 3.32% and return on assets (ROA) of 2.83% are below the industry median for specialty chemicals, which typically exceeds 5% ROE and 4% ROA. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's operating income of INR 84.77 million is derived from a gross profit of INR 242.87 million, indicating a relatively low-margin business model. Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and 3.2% in the next fiscal year, based on historical trends and industry benchmarks. However, the growth trajectory is modest compared to the industry average of 6-8% annual revenue growth for specialty chemicals firms. The company's capital expenditure of INR 164.53 million is primarily directed toward maintaining existing production capacity rather than expanding it. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The dilution potential is also low, as the number of basic and diluted shares outstanding is identical, indicating no imminent share issuance. The company has not made any recent public filings or disclosures that would suggest a material change in its risk profile. The company has not issued any recent earnings transcripts or 10-K filings that would provide additional insight into its strategic direction or operational performance. The absence of recent public commentary may limit visibility into the company's long-term growth plans and competitive positioning.

30-day price · HPAD+7.48 (+25.5%)
Low$27.61High$47.42Close$36.81As of17 May, 00:00 UTC
Profile
CompanyHp Adhesives Ltd
TickerHPAD.NS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Hp Adhesives Ltd is a specialty chemicals company that produces and sells adhesives, primarily used in industrial and consumer applications.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

Hp Adhesives Ltd maintains a strong liquidity position, with a current ratio of 4.61, indicating the company can easily cover its short-term obligations. The company's liquidity FPT (Fundamental Price Target) is supported by a robust operating cash flow of INR 227.84 million and a cash and equivalents balance of INR 90.99 million. The debt-to-equity ratio of 0.02 suggests a conservative capital structure with minimal leverage. In terms of profitability, the company's return on equity (ROE) of 3.32% and return on assets (ROA) of 2.83% are below the industry median for specialty chemicals, which typically exceeds 5% ROE and 4% ROA. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's operating income of INR 84.77 million is derived from a gross profit of INR 242.87 million, indicating a relatively low-margin business model. Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and 3.2% in the next fiscal year, based on historical trends and industry benchmarks. However, the growth trajectory is modest compared to the industry average of 6-8% annual revenue growth for specialty chemicals firms. The company's capital expenditure of INR 164.53 million is primarily directed toward maintaining existing production capacity rather than expanding it. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The dilution potential is also low, as the number of basic and diluted shares outstanding is identical, indicating no imminent share issuance. The company has not made any recent public filings or disclosures that would suggest a material change in its risk profile. The company has not issued any recent earnings transcripts or 10-K filings that would provide additional insight into its strategic direction or operational performance. The absence of recent public commentary may limit visibility into the company's long-term growth plans and competitive positioning.
Key takeaways
  • The company maintains a strong liquidity position with a current ratio of 4.61 and a low debt-to-equity ratio of 0.02.
  • Return on equity and return on assets are below industry medians, indicating underperformance in capital efficiency.
  • Revenue is concentrated in a single business segment with no disclosed geographic diversification.
  • Revenue growth is projected to be modest at 4.5% for the current fiscal year and 3.2% for the next.
  • The company presents low liquidity and dilution risk, with no immediate filing-based flags detected.
  • Recent public filings or transcripts are limited, reducing visibility into strategic direction.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$593.5M
Gross profit$242.9M
Operating income$84.8M
Net income$56.1M
R&D
SG&A
D&A
SBC
Operating cash flow$227.8M
CapEx-$164.5M
Free cash flow
Total assets$1.98B
Total liabilities$289.2M
Total equity$1.69B
Cash & equivalents$91.0M
Long-term debt$31.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.18B$113.0M$100.6M-$44.4M
FY-3$1.65B$124.8M$60.1M-$85.5M
FY-2$2.33B$144.5M$108.6M-$19.1M
FY-1$2.36B$267.5M$205.7M$84.1M
FY0$2.53B$213.5M$182.4M$61.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$897.8M$126.6M$1.0M
FY-3$1.95B$1.37B$475.0M
FY-2$1.85B$1.48B$0.00
FY-1$1.98B$1.69B$0.00
FY0$2.28B$1.84B$26.9M
PeriodOCFCapExFCFSBC
FY-4$112.6M-$164.0M-$44.4M
FY-3-$102.1M-$174.0M-$85.5M
FY-2-$50.5M-$160.1M-$19.1M
FY-1$227.8M-$164.5M$84.1M
FY0$99.4M-$140.3M$61.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$593.5M$84.8M$56.1M
FQ-6$605.2M$64.1M$56.1M
FQ-5$589.3M$53.7M$41.7M
FQ-4$666.8M$51.0M$42.1M
FQ-3$667.4M$44.3M$42.5M
FQ-2$661.0M$51.2M$41.9M
FQ-1$650.6M$45.9M$35.3M
FQ0$653.7M$19.6M$16.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.98B$1.69B$91.0M
FQ-6
FQ-5$2.05B$1.76B$117.3M
FQ-4
FQ-3$2.28B$1.84B$31.6M
FQ-2
FQ-1$2.32B$1.88B$61.1M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$227.8M-$164.5M
FQ-6
FQ-5$118.1M-$47.4M
FQ-4
FQ-3$99.4M-$140.3M
FQ-2
FQ-1$109.7M-$25.7M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.69B
Net cash$59.3M
Current ratio4.6
Debt/Equity0.0
ROA2.8%
ROE3.3%
Cash conversion4.1%
CapEx/Revenue-27.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricHPADActivity
Op margin14.3%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin9.4%4.1% medp25 0.1% · p75 8.8%top quartile
Gross margin40.9%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-27.7%-6.2% medp25 -13.4% · p75 -2.6%bottom quartile
Debt / equity2.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 11:31 UTC#06485422
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 03:39 UTCJob: 25de183e